Publications of Leo I Gordon - Northwestern Scholars

193 Publications

This view shows all the publications associated to this researcher. Select a tab to view the documents within each secion. If you are an authorized user, you can add content by selecting the Edit your profile button above. Access to this tool is managed by a project team at your institution.

Jump to:

Books
Book Chapters
Conference Proceedings
Meeting Abstracts
Presentations
Technical Reports
Other Written Works

193 Publications from Scopus

This is a list of publications by this researcher, listed chronologically starting with the most recent first. New publications appear in this list weekly. The source of publications and 'cited by' data for this application is Scopus.

sort by year | cited by

Select All | Save icon

Export

1.
2013

Ekaterina Lesovaya; Alexander Yemelyanov; Kirill Kirsanov; Alexander Popa; Gennady Belitsky; Marianna Yakubovskaya; Leo I. Gordon; Steven T. Rosen; Irina Budunova

Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies
Cell Cycle. 2013;12(1):133-144.

0
2.
2013

Jenny Zhang; Vladimir Grubor; Cassandra L. Love; Anjishnu Banerjee; Kristy L. Richards; Piotr A. Mieczkowski; Cherie Dunphy; William Choi; Wing Yan Au; Gopesh Srivastava; et al.

Genetic heterogeneity of diffuse large B-cell lymphoma
Proceedings of the National Academy of Sciences of the United States of America. 2013;110(4):1398-1403.

0
3.
2013

Rupali Roy; Andrew M. Evens; David Patton; Lillia Gallot; Annette Larson; Alfred Rademaker; Jeffrey Cilley; Stewart Spies; Daina Variakojis; Leo I. Gordon; et al.

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: A phase i trial of combined induction therapy and bortezomib consolidation
Leukemia and Lymphoma. 2013;54(3):497-502.

0
4.
2013

Shuo Yang; Marina G. Damiano; Heng Zhang; Sushant Tripathy; Andrea J. Luthi; Jonathan S. Rink; Andrey V. Ugolkov; Amareshwar T. K. Singh; Sandeep S. Dave; Leo I. Gordon; et al.

Biomimetic, synthetic HDL nanostructures for lymphoma
Proceedings of the National Academy of Sciences of the United States of America. 2013;110(7):2511-2516.

0
5.
2013

Andrew M. Evens; Fangxin Hong; Leo I. Gordon; Richard I. Fisher; Nancy L. Bartlett; Joseph M. Connors; Randy D. Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D. Cheson; et al.

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: A comprehensive analysis from the North American intergroup trial E2496
British Journal of Haematology. 2013;161(1):76-86.

0
6.
2013

Richard W. Ahn; Susan L. Barrett; Meera R. Raja; Jennifer K. Jozefik; Lidia Spaho; Haimei Chen; Marcel B. Bally; Andrew P. Mazar; Michael J. Avram; Jane N. Winter; et al.

Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo
PLoS ONE. 2013;8(3).

0
7.
2013

Leo I. Gordon; Fangxin Hong; Richard I. Fisher; Nancy L. Bartlett; Joseph M. Connors; Randy D. Gascoyne; Henry Wagner; Patrick J. Stiff; Bruce D. Cheson; Mary Gospodarowicz; et al.

Randomized phase III trial ofabvdversus stanfordvwith or without radiation therapy in locally extensive and advanced-stage hodgkin lymphoma: An intergroup study coordinated by the eastern cooperative oncology group (E2496)
Journal of Clinical Oncology. 2013;31(6):684-691.

3
8.
2013

A.M. Evens; S. Choquet; A.R. Kroll-Desrosiers; D. Jagadeesh; S.M. Smith; F. Morschhauser; V. Leblond; R. Roy; B. Barton; L.I. Gordon; et al.

Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
American Journal of Transplantation. 2013.

0
9.
2013

David W. Scott; Fong Chun Chan; Fangxin Hong; Sanja Rogic; King L. Tan; Barbara Meissner; Susana Ben-Neriah; Merrill Boyle; Robert Kridel; Adele Telenius; et al.

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical hodgkin lymphoma
Journal of Clinical Oncology. 2013;31(6):692-700.

0
10.
2013

Andrew D. Zelenetz; William G. Wierda; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; Naresh Bellam; John C. Byrd; Myron S. Czuczman; Luis E. Fayad; et al.

Non-Hodgkin's lymphomas, version 1.2013: Featured updates to the NCCN guidelines
JNCCN Journal of the National Comprehensive Cancer Network. 2013;11(3):257-273.

0
11.
2012

Ann S. LaCasce; Jonathan L. Vandergrift; Maria A. Rodriguez; Gregory A. Abel; Allison L. Crosby; Myron S. Czuczman; Auayporn P. Nademanee; Douglas W. Blayney; Leo I. Gordon; Michael Millenson; et al.

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database
Blood. 2012;119(9):2093-2099.

6
12.
2012

Leo I. Gordon; Richard Longnecker

Off-targeting oft-targeted CD20 in cHL
Blood. 2012;119(18):4095-4096.

0
13.
2012

Anita Kumar; Ann Vanderplas; Ann S. Lacasce; Maria A. Rodriguez; Allison L. Crosby; Eva Lepisto; Myron S. Czuczman; Auayporn Nademanee; Joyce Niland; Leo I. Gordon; et al.

Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database
Cancer. 2012;118(11):2944-2951.

1
14.
2012

Peter H. Wiernik; Hailun Li; Edie Weller; Howard S. Hochster; Sandra J. Horning; Tipu Nazeer; Leo I. Gordon; Thomas M. Habermann; Carl J. Minniti Jr.; Gary R. Shapiro; et al.

Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: Long-term follow-up of an Eastern Cooperative Oncology Group study (E5493)
Leukemia and Lymphoma. 2012;53(6):1137-1142.

0
15.
2012

Gregory A. Abel; Ann Vanderplas; Maria A. Rodriguez; Allison L. Crosby; Myron S. Czuczman; Joyce C. Niland; Leo I. Gordon; Michael Millenson; Andrew D. Zelenetz; Jonathan W. Friedberg; et al.

High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database
Leukemia and Lymphoma. 2012;53(6):1113-1116.

3
16.
2012

Richard T. Hoppe; Ranjana H. Advani; Weiyun Z. Ai; Richard F. Ambinder; Patricia Aoun; Celeste M. Bello; Philip J. Bierman; Kristie A. Blum; Robert Chen; Bouthaina Dabaja; et al.

Hodgkin lymphoma, version 2.2012: Featured updates to the NCCN guidelines
JNCCN Journal of the National Comprehensive Cancer Network. 2012;10(5):589-597.

3
17.
2012

Jamie L. Dargart; Kamonwan Fish; Leo I. Gordon; Richard Longnecker; Osman Cen

Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A
Antiviral Research. 2012;95(1):49-56.

1
18.
2012

Andrew M. Evens; Irene Helenowski; Erika Ramsdale; Chadi Nabhan; Reem Karmali; Britt Hanson; Benjamin Parsons; Scott Smith; Annette Larsen; June M. McKoy; et al.

A retrospective multicenter analysis of elderly Hodgkin lymphoma: Outcomes and prognostic factors in the modern era
Blood. 2012;119(3):692-695.

4
19.
2012

Anas Younes; Stella Kim; Jorge Romaguera; Amanda Copeland; Silvanade De Castro Farial; Larry W. Kwak; Luis Fayad; Frederick Hagemeister; Michelle Fanale; Sattva Neelapu; et al.

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
Journal of Clinical Oncology. 2012;30(22):2776-2782.

5
20.
2012

Antonella Sassano; Jessica K. Altman; Leo I. Gordon; Leonidas C. Platanias

Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation
Leukemia and Lymphoma. 2012;53(9):1779-1784.

0
21.
2012

Mitchell R. Smith; Hailun Li; Leo Gordon; Randy D. Gascoyne; Elisabeth Paietta; Andres Forero-Torres; Brad S. Kahl; Ranjana Advani; Fangxin Hong; Sandra J. Horning

Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90- ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group study E1499
Journal of Clinical Oncology. 2012;30(25):3119-3126.

2
22.
2012

King L. Tan; David W. Scott; Fangxin Hong; Brad S. Kahl; Richard I. Fisher; Nancy L. Bartlett; Ranjana H. Advani; Rena Buckstein; Lisa M. Rimsza; Joseph M. Connors; et al.

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial
Blood. 2012;120(16):3280-3287.

3
23.
2012

Philippe Solal-Ceĺigny; Monica Bellei; Luigi Marcheselli; Emanuela Anna Pesce; Stefano Pileri; Peter McLaughlin; Stefano Luminari; Barbara Pro; Silvia Montoto; Andrés J. M. Ferreri; et al.

Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: Results of an F2-study database
Journal of Clinical Oncology. 2012;30(31):3848-3853.

2
24.
2012

Cassandra Love; Zhen Sun; Dereje Jima; Guojie Li; Jenny Zhang; Rodney Miles; Kristy L. Richards; Cherie H. Dunphy; William L. Choi; Gopesh Srivastava; et al.

The genetic landscape of mutations in Burkitt lymphoma
Nature Genetics. 2012;44(12):1321-1325.

4
25.
2012

Andrew D. Zelenetz; William G. Wierda; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; Naresh Bellam; John C. Byrd; Myron S. Czuczman; Luis Fayad; et al.

Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines
JNCCN Journal of the National Comprehensive Cancer Network. 2012;10(12):1487-1498.

0
26.
2011

Mistuni Ghosh; Amareshwar T.K. Singh; Wenwei Xu; Todd Sulchek; Leo I. Gordon; Robert O. Ryan

Curcumin nanodisks: Formulation and characterization
Nanomedicine: Nanotechnology, Biology, and Medicine. 2011;7(2):162-167.

9
27.
2011

Andrew D. Zelenetz; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; Nancy Bartlett; Naresh Bellam; John C. Byrd; Myron S. Czuczman; Luis E. Fayad; Martha J. Glenn; et al.

Non-Hodgkin's lymphomas: Clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network. 2011;9(5):484-560.

14
28.
2011

Rupali Roy; Leo I. Gordon

Optimization of postremission therapy in follicular lymphoma: Efficacy of rituximab maintenance
JNCCN Journal of the National Comprehensive Cancer Network. 2011;9(5):563-571.

0
29.
2011

Thomas E. Witzig; Paul Fishkin; Leo I. Gordon; Stephanie A. Gregory; Samuel Jacobs; Roger MacKlis; Peter McLaughlin; Oliver Press; Andrew D. Zelenetz

Treatment recommendations for radioimmunotherapy in follicular lymphoma: A consensus conference report
Leukemia and Lymphoma. 2011;52(7):1188-1199.

7
30.
2011

Amareshwar T. K. Singh; Mistuni Ghosh; Trudy M. Forte; Robert O. Ryan; Leo I. Gordon

Curcumin nanodisk-induced apoptosis in mantle cell lymphoma
Leukemia and Lymphoma. 2011;52(8):1537-1543.

6
31.
2011

Savita Bhalla; Andrew M. Evens; Bojie Dai; Sheila Prachand; Leo I. Gordon; Ronald B. Gartenhaus

The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma
Blood. 2011;118(4):1052-1061.

2
32.
2011

Yi-Hua Chen; Amy Chadburn; Andrew M. Evens; Jane N. Winter; Leo I. Gordon; Anjen Chenn; Charles Goolsby; LoAnn Peterson

Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8- γδ T-cell large granular lymphocytic leukemia
American Journal of Clinical Pathology. 2011;136(2):289-299.

4
33.
2011

Richard T. Hoppe; Ranjana H. Advani; Weiyun Z. Ai; Richard F. Ambinder; Celeste M. Bello; Philip J. Bierman; Kristie A. Blum; Bouthaina Dabaja; Ysabel Duron; Andres Forero; et al.

Hodgkin lymphoma: Clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network. 2011;9(9):1020-1058.

5
34.
2010

Denise M. Oliansky; Leo I. Gordon; Jerry King; Ginna Laport; John P. Leonard; Peter McLaughlin; Robert J. Soiffer; Koen W. van Besien; Michael Werner; Roy B. Jones; et al.

The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review
Biology of Blood and Marrow Transplantation. 2010;16(4):443-468.

12
35.
2010

Andrew D. Zelenetz; Jeremy S. Abramson; Ranjana H. Advani; C. Babis Andreadis; John C. Byrd; Myron S. Czuczman; Luis Fayad; Andres Forero; Martha J. Glenn; Jon P. Gockerman; et al.

Non-Hodgkin's lymphomas clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network. 2010;8(3):288-334.

55
36.
2010

Andrew M. Evens; Laurie H. Sehn; Pedro Farinha; Beverly P. Nelson; Adekunle Raji; Yi Lu; Adam Brakman; Vamsi Parimi; Jane N. Winter; Paul T. Schumacker; et al.

Hypoxia-inducible factor-1 α expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOP
Journal of Clinical Oncology. 2010;28(6):1017-1024.

14
37.
2010

Andrew M. Evens; Kevin A. David; Irene Helenowski; Beverly Nelson; Dixon Kaufman; Sheetal M. Kircher; Alla Gimelfarb; Elise Hattersley; Lauren A. Mauro; Borko Jovanovic; et al.

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era
Journal of Clinical Oncology. 2010;28(6):1038-1046.

47
38.
2010

Amareshwar T. K. Singh; Andrew M. Evens; Sheila N. Prachand; Leo I. Gordon

Motexafin gadolinium enhances p53-Mdm2 interactions, reducing p53 and downstream targets in lymphoma cell lines
Anticancer Research. 2010;30(4):1131-1136.

2
39.
2010

Sairah Ahmed; Jane N. Winter; Leo I. Gordon; Andrew M. Evens

Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: Current status and future applications
Leukemia and Lymphoma. 2010;51(7):1163-1177.

10
40.
2010

Amareshwar T.K. Singh; Andrew M. Evens; Reilly J. Anderson; Jennifer A. Beckstead; Natesan Sankar; Antonella Sassano; Savita Bhalla; Shuo Yang; Leonidas C. Platanias; Trudy M. Forte; et al.

All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma
British Journal of Haematology. 2010;150(2):158-169.

9
41.
2010

Savita Bhalla; Leo I. Gordon; Kevin David; Sheila Prachand; Amareshwar T.K. Singh; Shuo Yang; Jane N. Winter; Dongsheng Guo; Thomas O'Halloran; Leonidas C. Platanias; et al.

Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms: Correspondence
British Journal of Haematology. 2010;150(3):365-369.

3
42.
2010

Shuo Yang; Andrew M. Evens; Sheila Prachand; Amareshwar T. K. Singh; Savita Bhalla; Kevin David; Leo I. Gordon

Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata
Clinical Cancer Research. 2010;16(19):4755-4768.

12
43.
2010

Dereje D. Jima; Jenny Zhang; Cassandra Jacobs; Kristy L. Richards; Cherie H. Dunphy; William W. L. Choi; Wing Yan Au; Gopesh Srivastava; Magdalena B. Czader; David A. Rizzieri; et al.

Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs
Blood. 2010;116(23):e118-e127.

38
44.
2010

Andrew M. Evens; Rupali Roy; Danielle Sterrenberg; Michelle Z. Moll; Amy Chadburn; Leo I. Gordon

Post-transplantation lymphoproliferative disorders: Diagnosis, prognosis, and current approaches to therapy
Current Oncology Reports. 2010;12(6):383-394.

21
45.
2009

Jayesh Mehta; Olga Frankfurt; Jessica Altman; Andrew Evens; Martin Tallman; Leo Gordon; Stephanie Williams; Jane Winter; Jairam Krishnamurthy; Sara Duffey; et al.

Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation
Leukemia and Lymphoma. 2009;50(9):1434-1441.

3
46.
2009

Leo I. Gordon; Michael A. Burke; Amareshwar T. K. Singh; Sheila Prachand; Elliot D. Lieberman; Lin Sun; Tejaswitha Jairaj Naik; Sathyamangla V. Naga Prasad; Hossein Ardehali

Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways
Journal of Biological Chemistry. 2009;284(4):2080-2087.

31
47.
2009

V. Singh; J. Krishnamurthy; S. Duffey; R. Meagher; M. Villa; J. Monreal; A. Evens; O. Frankfurt; J. Altman; et al.

Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
Bone Marrow Transplantation. 2009;43(4):301-305.

4
48.
2009

Owen A. O'Connor; Craig Moskowitz; Carol Portlock; Paul Hamlin; David Straus; Otilia Dumitrescu; Debra Sarasohn; Mithat Gonen; John Butos; Ellen Neylon; et al.

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: Results of a multicentre phase 2 clinical trial
British Journal of Haematology. 2009;145(1):34-39.

27
49.
2009

Howard Hochster; Edie Weller; Randy D. Gascoyne; Thomas M. Habermann; Leo I. Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J. Horning

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: Results of the randomized phase III ECOG1496 study
Journal of Clinical Oncology. 2009;27(10):1607-1614.

122
50.
2009

Jane N. Winter; David J. Inwards; Stewart Spies; Gregory Wiseman; David Patton; William Erwin; Alfred W. Rademaker; Bing Bing Weitner; Stephanie F. Williams; Martin S. Tallman; et al.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-hodgkin's lymphoma
Journal of Clinical Oncology. 2009;27(10):1653-1659.

32
51.
2009

Savita Bhalla; Sriram Balasubramanian; Kevin David; Mint Sirisawad; Joseph Buggy; Lauren Mauro; Sheila Prachand; Richard Miller; Leo I. Gordon; Andrew M. Evens

PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-κB mechanisms and is synergistic with bortezomib in lymphoma cells
Clinical Cancer Research. 2009;15(10):3354-3365.

29
52.
2009

Kenneth R. Carson; Andrew M. Evens; Elizabeth A. Richey; Thomas M. Habermann; Daniele Focosi; John F. Seymour; Jacob Laubach; Susie D. Bawn; Leo I. Gordon; Jane N. Winter; et al.

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood. 2009;113(20):4834-4840.

331
53.
2009

Andrew M. Evens; William G. Spies; Irene B. Helenowski; David Patton; Stewart Spies; Borko D. Jovanovic; Sarah Miyata; Elizabeth Hamilton; Daina Variakojis; Jun Chen; et al.

The novel expanded porphyrin, motexafin gadolinium, combined with [ ⁹⁰Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: Preclinical findings and results of a phase I trial
Clinical Cancer Research. 2009;15(20):6462-6471.

3
54.
2008

Andrew M. Evens; Jane N. Winter; Nanjiang Hou; Beverly P. Nelson; Alfred Rademaker; David Patton; Seema Singhal; Olga Frankfurt; Martin S. Tallman; et al.

A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: Long-term follow-up in newly diagnosed mantle cell lymphoma
British Journal of Haematology. 2008;140(4):385-393.

26
55.
2008

Andrew D. Zelenetz; Ranjana H. Advani; John C. Byrd; Myron S. Czuczman; Lloyd E. Damon; Madeleine Duvic; Luis Fayad; Andres Forero; Martha J. Glenn; Jon P. Gockerman; et al.

Non-Hodgkin's lymphomas
JNCCN Journal of the National Comprehensive Cancer Network. 2008;6(4):356-421.

11
56.
2008

Andrew M. Evens; Paul T. Schumacker; Irene B. Helenowski; Amareshwar T. K. Singh; Danijela Dokic; Anjeni Keswani; Elizabeth Kordeluk; Adekunle Raji; Jane N. Winter; Borko D. Jovanovic; et al.

Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family
British Journal of Haematology. 2008;141(5):676-680.

14
57.
2008

Richard T. Hoppe; Ranjana Hira Advani; Richard F. Ambinder; Philip J. Bierman; Clara D. Bloomfield; Kristie Blum; Bouthaina Dabaja; Benjamin Djulbegovic; Andres Forero; Leo I. Gordon; et al.

Hodgkin disease/lymphoma
JNCCN Journal of the National Comprehensive Cancer Network. 2008;6(6):594-622.

3
58.
2008

Katalin Kelemen; LoAnn C. Peterson; Irene Helenowski; Charles L. Goolsby; Borko Jovanovic; Sarah Miyata; Olivia Aranha; Steven T. Rosen; Jane N. Winter; Beverly P. Nelson; et al.

CD23+ mantle cell lymphoma: A clinical pathologic entity associated with superior outcome compared with CD23- disease
American Journal of Clinical Pathology. 2008;130(2):166-177.

18
59.
2008

Lode J. Swinnen; Michael Leblanc; Thomas M. Grogan; Leo I. Gordon; Patrick J. Stiff; Alan M. Miller; Yvette Kasamon; Thomas P. Miller; Richard I. Fisher

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder
Transplantation. 2008;86(2):215-222.

25
60.
2007

A.M. Evens; J.K. Altman; B.B. Mittal; N. Hou; A. Rademaker; D. Patton; L. Kaminer; S. Williams; S. Duffey; D. Variakojis; et al.

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma
Annals of Oncology. 2007;18(4):679-688.

10
61.
2007

Steve Trifilio; Gennethel Pennick; Judy Pi; Jennifer Zook; Mary Golf; Kimberley Kaniecki; Seema Singhal; Stephanie Williams; Jane Winter; Martin Tallman; et al.

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients
Cancer. 2007;109(8):1532-1535.

116
62.
2007

Thomas E. Witzig; Arturo Molina; Leo I. Gordon; Christos Emmanouilides; Russell J. Schilder; Ian W. Flinn; Mohamed Darif; Roger Macklis; Katie Vo; et al.

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
Cancer. 2007;109(9):1804-1810.

85
63.
2007

Andrew M. Evens; Jeffrey Cilley; Taylor Ortiz; Mrinal Gounder; Nanjiang Hou; Alfred Rademaker; Sarah Miyata; Kara Catsaros; Connie Augustyniak; Charles L. Bennett; et al.

G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: Low toxicity and excellent outcomes in a 10-year analysis
British Journal of Haematology. 2007;137(6):545-552.

29
64.
2007

J.P. Leonard; J.W. Friedberg; A. Younes; D. Fisher; L.I. Gordon; J. Moore; M. Czuczman; T. Miller; P. Stiff; B.D. Cheson; et al.

A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
Annals of Oncology. 2007;18(7):1216-1223.

71
65.
2007

S. Trifilio; S. Singhal; S. Williams; O. Frankfurt; L. Gordon; A. Evens; J. Winter; M. Tallman; J. Pi; J. Mehta

Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole
Bone Marrow Transplantation. 2007;40(5):451-456.

100
66.
2007

Andrew M. Evens; Sheryl L. Ziegler; Rohit Gupta; Connie Augustyniak; Leo I. Gordon; Jayesh Mehta

Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma
Clinical Lymphoma and Myeloma. 2007;7(7):472-474.

4
67.
2007

Myron S. Czuczman; Christos Emmanouilides; Mohamed Darif; Thomas E. Witzig; Leo I. Gordon; Stephen Revell; Katie Vo; Arturo Molina

Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy
Journal of Clinical Oncology. 2007;25(27):4285-4292.

50
68.
2007

Gregory A. Wiseman; Peter S. Conti; Katie Vo; Russell J. Schilder; Leo I. Gordon; Christos Emmanouilides; Dan H. Silverman; Thomas E. Witzig; Mohamed Darif; et al.

Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Clinical Lymphoma and Myeloma. 2007;7(8):514-517.

2
69.
2007

Christos Emmanouilides; Thomas E. Witzig; Gregory A. Wiseman; Leo I. Gordon; Hua Wang; Russell Schilder; M. Wayne Saville; Ian Flinn; Arturo Molina

Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma
Cancer Biotherapy and Radiopharmaceuticals. 2007;22(5):684-691.

21
70.
2006

J. Mehta; L.I. Gordon; M.S. Tallman; J.N. Winter; A.O. Evens; O. Frankfurt; S.F. Williams; D. Grinblatt; L. Kaminer; R. Meagher; et al.

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?
Bone Marrow Transplantation. 2006;38(2):95-100.

16
71.
2006

Kristen Ganjoo; Caroline An; Michael Robertson; Leo Gordon; Joy Sen; Jill Weisenbach; Shuli Li; Edie Weller; Attilio Orazi; Sandra Horning

Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis
Leukemia and Lymphoma. 2006;47(6):998-1005.

65
72.
2006

S. Singhal; L.I. Gordon; M.S. Tallman; J.N. Winter; A.M. Evens; O. Frankfurt; S.F. Williams; D. Grinblatt; L. Kaminer; et al.

Erratum: Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? (Bone Marrow Transplatation (2006) vol. 38 (95-100) 10.1037/sj.bmt.1705477)
Bone Marrow Transplantation. 2006;38(5):397.

0
73.
2006

S. Singhal; L.I. Gordon; M.S. Tallman; J.N. Winter; A.M. Evens; O. Frankfurt; S.F. Williams; D. Grinblatt; L. Kaminer; et al.

Erratum: Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation (Bone Marrow Transplatation (2006) vol. 37 (553-557) 10.1038/sj.bmt.1705282)
Bone Marrow Transplantation. 2006;38(5):397.

0
74.
2006

Beverly P. Nelson; Diana Treaba; Charles Goolsby; Stephanie Williams; Gordon Dewald; Leo Gordon; Loann C. Peterson

Surface immunoglobulin positive lymphoblastic leukemia in adults; a genetic spectrum
Leukemia and Lymphoma. 2006;47(7):1352-1359.

1
75.
2006

S. Singhal; L.I. Gordon; M.S. Tallman; J.N. Winter; A.O. Evens; O. Frankfurt; S.F. Williams; D. Grinblatt; L. Kaminer; et al.

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation. 2006;37(6):553-557.

7
76.
2006

Andrew D. Zelenetz; Ranjana H. Advani; Francis Buadi; Fernando Cabanillas; Michael A. Caligiuri; Myron S. Czuczman; Lloyd E. Damon; Luis Fayad; Ian W. Flinn; Andres Forero; et al.

Non-Hodgkin's lymphoma: Clinical practice guidelines in oncology™
JNCCN Journal of the National Comprehensive Cancer Network. 2006;4(3):258-310.

18
77.
2006

Richard T. Hoppe; Ranjana Hira Advani; Philip J. Bierman; Clara D. Bloomfield; Francis Buadi; Benjamin Djulgegovic; Andres Forero; Leo I. Gordon; Francisco J. Hernandez-Ilizaliturri; Mark S. Kaminski; et al.

Hodgkin disease/lymphoma: Clinical practice guidelines in oncology™
JNCCN Journal of the National Comprehensive Cancer Network. 2006;4(3):210-230.

21
78.
2006

S. Singhal; L.I. Gordon; M.S. Tallman; J.N. Winter; A.O. Evens; O. Frankfurt; S.F. Williams; D. Grinblatt; L. Kaminer; R. Meagher; et al.

Erratum: Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation (Bone Marrow Transplantation (2006) vol. 37 (553-557) 10.1038/sj.bmt.1705282)
Bone Marrow Transplantation. 2006;37(11):1067.

1
79.
2006

Christos Emmanouilides; Thomas E. Witzig; Leo I. Gordon; Katie Vo; Gregory A. Wiseman; Ian W. Flinn; Mohamed Darif; Russell J. Schilder; Arturo Molina

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma
Leukemia and Lymphoma. 2006;47(4):629-636.

56
80.
2006

S. Trifilio; L. Gordon; S. Singhal; M. Tallman; A. Evens; K. Rashid; M. Fishman; K. Masino; J. Pi; J. Mehta

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia
Bone Marrow Transplantation. 2006;37(11):997-1001.

29
81.
2005

Leo Gordon

A green tea component, catechin, rapidly induces apoptosis of myeloid leukemic cells via modulation of reactive oxygen species production in vitro and inhibits tumor growth in vivo.
Haematologica. 2005;90(3):290.

0
82.
2005

Leo I. Gordon

Flu redux and RIT: Friendly fire in the treatment of low-grade lymphoma
Blood. 2005;105(12):4543-4544.

0
83.
2005

Myron S. Czuczman; Aron Thall; Thomas E. Witzig; Julie M. Vose; Anas Younes; Christos Emmanouilides; Thomas P. Miller; Joseph O. Moore; John P. Leonard; Leo I. Gordon; et al.

Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma
Journal of Clinical Oncology. 2005;23(19):4390-4398.

102
84.
2005

Andrew M. Evens; Lakshmi Balasubramanian; Leo I. Gordon

Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies
Current Treatment Options in Oncology. 2005;6(4):289-296.

12
85.
2005

M. Tomblyn; L.I. Gordon; S. Singhal; M.S. Tallman; S. Williams; J.N. Winter; A. Evens; J. Mehta

Use of total leukocyte and platelet counts to guide stem cell apheresis in healthy allogeneic donors treated with G-CSF
Bone Marrow Transplantation. 2005;36(8):663-666.

7
86.
2005

Lodovico Balducci; Harvey Jay Cohen; Paul F. Engstrom; David S. Ettinger; Jeffrey Halter; Leo I. Gordon; Krystyna Kiel; Andrew Kneier; Dean Lim; Stephen H. Petersdorf; et al.

Senior adult oncology clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network. 2005;3(4):572-590.

38
87.
2005

Andrew M. Evens; Philip Lecane; Darren Magda; Sheila Prachand; Seema Singhal; Jeff Nelson; Richard A. Miller; Ronald B. Gartenhaus; Leo I. Gordon

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells
Blood. 2005;105(3):1265-1273.

41
88.
2005

A. Gidron; A. Verma; M. Doyle; L. Boggio; A. Evens; L. Gordon; S. Singhal; M. Tallman; S. Wlliams; J. Winter; et al.

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?
Bone Marrow Transplantation. 2005;35(3):243-246.

16
89.
2004

Stephen M. Ansell; Russell J. Schilder; Peter C. Pieslor; Leo I. Gordon; Christos Emmanouilides; Katie Vo; Myron S. Czuczman; Thomas E. Witzig; Charles Theuer; Arturo Molina

Antilymphoma treatments given subsequent to yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: A review of the literature
Clinical Lymphoma. 2004;5(3):202-204.

34
90.
2004

A. Verma; J. Pedicano; S. Trifilio; S. Singhal; M. Tallman; J. Winter; S. Williams; L. Gordon; J. Monreal; J. Mehta

How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?
Bone Marrow Transplantation. 2004;33(7):715-719.

4
91.
2004

Russell Schilder; Arturo Molina; Nancy Bartlett; Thomas Witzig; Leo Gordon; James Murray; Stewart Spies; Hua Wang; Gregory Wiseman; Christine White

Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia
Cancer Biotherapy and Radiopharmaceuticals. 2004;19(4):478-481.

29
92.
2004

A.M. Evens; J. Mehta; L.I. Gordon

Rust and corrosion in hematopoietic stem cell transplantation: The problem of iron and oxidative stress
Bone Marrow Transplantation. 2004;34(7):561-571.

46
93.
2004

Leo I. Gordon; Thomas Witzig; Arturo Molina; Myron Czuczman; Christos Emmanouilides; Robin Joyce; Katie Vo; Charles Theuer; Brad Pohlman; Nancy Bartlett; et al.

Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma
Clinical Lymphoma. 2004;5(2):98-101.

83
94.
2004

Andrew M. Evens; Leo I. Gordon

Radioimmunotherapy in non-Hodgkin's lymphoma: Trials of yttrium 90-labeled ibritumomab tiuxetan and beyond
Clinical Lymphoma. 2004;5(SUPPL. 1):S11-S15.

4
95.
2004

Chadi Nabhan; David Patton; Leo I. Gordon; Mary B. Riley; Timothy Kuzel; Martin S. Tallman; Steven T. Rosen

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
Leukemia and Lymphoma. 2004;45(11):2269-2273.

44
96.
2004

J. Cilley; C. Rihn; J. Monreal; L.I. Gordon; S. Singhal; M. Tallman; S. Williams; J. Winter; J. Mehta

Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopietic stem cell transplantation?
Bone Marrow Transplantation. 2004;33(2):161-164.

7
97.
2004

Andrew M. Evens; Sheila Prachand; Bo Shi; Mary Paniaqua; Leo I. Gordon; Ronald B. Gartenhaus

Imexon-Induced Apoptosis in Multiple Myeloma Tumor Cells is Caspase-8 Dependent
Clinical Cancer Research. 2004;10(4):1481-1491.

23
98.
2004

Mary Beth Riley; Leo I. Gordon

Efficacy and safety of radioimmuno-therapy with yttrium 90 ibritumomab tiuxetan (Zevalin)
Seminars in Oncology Nursing. 2004;20(SUPPL. 1):8-13.

1
99.
2004

Leo I. Gordon; Arturo Molina; Thomas Witzig; Christos Emmanouilides; Andrew Raubtischek; Mohamed Darif; Russell J. Schilder; Greg Wiseman; Christine A. White

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20⁺ B-cell lymphoma: Long-term follow-up of a phase 1/2 study
Blood. 2004;103(12):4429-4431.

136
100.
2003

M.Y. Ali; Y. Oyama; J. Monreal; J.N. Winter; M.S. Tallman; S.F. Williams; S. Singhal; L.I. Gordon; Jayesh Mehta

Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?
Bone Marrow Transplantation. 2003;31(10):861-864.

12
101.
2003

Thomas E. Witzig; Christine A. White; Leo I. Gordon; Gregory A. Wiseman; Christos Emmanouilides; James L. Murray; John Lister; Pratik S. Multani

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma
Journal of Clinical Oncology. 2003;21(7):1263-1270.

206
102.
2003

Bo Shi; Hsin-Ling Hsu; Andy M. Evens; Leo I. Gordon; Ronald B. Gartenhaus

Expression of the candidate MCT-1 oncogene in B- and T-cell lymphoid malignancies
Blood. 2003;102(1):297-302.

21
103.
2003

Leo I. Gordon

Practical Considerations and Radiation Safety in Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)
Seminars in Oncology. 2003;30(6 SUPPL. 17):23-28.

8
104.
2002

J. Mehta; S. Singhal; L. Gordon; M. Tallman; S. Wiliams; R. Luyun; M.Y. Ali; Y. Oyama; M. Villa; T. Shook; et al.

Cobe spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells
Bone Marrow Transplantation. 2002;29(7):563-567.

15
105.
2002

Leo I Gordon; Thomas E Witzig; Greg A Wiseman; Ian W Flinn; Stewart S Spies; Daniel H Silverman; Christos Emmanuolides; Larry Cripe; Mansoor Saleh; Myron S Czuczman; et al.

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma
Seminars in Oncology. 2002;29(1 SUPPL. 2):87-92.

48
106.
2002

Ronald B. Gartenhaus; Sheila N. Prachand; Mary Paniaqua; Yuyu Li; Leo I. Gordon

Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: Enhancement of apoptosis by manipulation of cellular redox state
Clinical Cancer Research. 2002;8(2):566-572.

67
107.
2002

Xiaoping Sun; Leo I. Gordon; LoAnn C. Peterson

Transformation of follicular lymphoma to acute lymphoblastic leukemia
Archives of Pathology and Laboratory Medicine. 2002;126(8):997-998.

1
108.
2002

Andrew M Evens; Leo I Gordon

Burkitt's and Burkitt-like lymphoma.
Current treatment options in oncology. 2002;3(4):291-305.

17
109.
2002

Thomas E. Witzig; Ian W. Flinn; Leo I. Gordon; Christos Emmanouilides; Myron S. Czuczman; Mansoor N. Saleh; Larry Cripe; Gregory Wiseman; Teresa Olejnik; Pratik S. Multani; et al.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
Journal of Clinical Oncology. 2002;20(15):3262-3269.

411
110.
2002

M. Tomblyn; L. Gordon; S. Singhal; M. Tallman; S. Williams; J. Winter; J. Mehta

Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: Implications for symptomatic management of diarrhea
Bone Marrow Transplantation. 2002;30(8):517-519.

15
111.
2002

C. Nabhan; L.A. Peterson; S.A. Kent; M.S. Tallman; G. Dewald; P. Multani; L.I. Gordon

Secondary acute myelogenous leukemia with MLL gene rearrangement following radioimmunotherapy (RAIT) for non-Hodgkin's lymphoma
Leukemia and Lymphoma. 2002;43(11):2145-2149.

10
112.
2002

M.Y. Ali; Y. Oyama; J. Monreal; J. Winter; M. Tallman; L.I. Gordon; S. William; S. Singhal; J. Mehta

Reassessing the definition of myeloid engraftment after autotransplantation: It is not necessary to see 0.5 × 10⁹/I neutrophils on 3 consecutive days to define myeloid recovery
Bone Marrow Transplantation. 2002;30(11):749-752.

7
113.
2002

Thomas E. Witzig; Leo I. Gordon; Fernando Cabanillas; Myron S. Czuczman; Christos Emmanouilides; Robin Joyce; Brad L. Pohlman; Nancy L. Bartlett; Gregory A. Wiseman; Norman Padre; et al.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
Journal of Clinical Oncology. 2002;20(10):2453-2463.

699
114.
2002

Gregory A. Wiseman; Leo I. Gordon; Pratik S. Multani; Thomas E. Witzig; Stewart Spies; Nancy L. Bartlett; Russell J. Schilder; James L. Murray; Mansoor Saleh; Roberta S. Allen; et al.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial
Blood. 2002;99(12):4336-4342.

205
115.
2001

T.E. Witzig; L.I. Gordon; B.R. Leigh; G.A. Wiseman; C. Emmanouilides; M.S. Czuczman; J.L. Murray; C. Zhang; A.J. Grillo-Lopez; C.A. White

Baseline peripheral blood B-cell levels correlate with disease-free interval and response to zevalin radioimmunotherapy of relapsed non-hodgkin's lymphoma
Blood. 2001;96(11 PART II):252b.

2
116.
2001

G. Wiseman; L. Gordon; B. Leigh; T. Witzig; C. Emmanouilides; M. Czuczman; S. Shuey; A. Grillo-Löpez; C. White

Safety and efficacy of the zevalin radioimmunotherapy regimen arenotdevflnlshedbyextending the time interval between rituximab infusion and zevalin injection
Blood. 2001;96(11 PART II):251b.

3
117.
2001

G.A. Wiseman; L.I. Gordon; B.R. Leigh; T.E. Witzig; S. Spies; C. Emmanoulidies; M.S. Czuczman; D.A. Podoloff; M. Wakefield; et al.

Multicenter experience with the zevalin radiolabeling kit for radioimmunotherapy of non-hodgkin's lymphoma
Blood. 2001;96(11 PART II):251b.

0
118.
2001

J. Mehta; Y. Oyama; J. Winter; S. Williams; M. Tallman; S. Singhal; M. Villa; T. Shook; R. Burt; A. Traynor; et al.

CD34⁺ cell collection efficiency does not correlate with the preleukapheresis hematocrit
Bone Marrow Transplantation. 2001;28(6):597-601.

10
119.
2001

Hau C. Kwaan; Leo I. Gordon

Thrombotic microangiopathy in the cancer patient
Acta Haematologica. 2001;106(1-2):52-56.

39
120.
2001

M.S. Czuczman; A.J. Grillo-López; P. McLaughlin; C.A. White; M. Saleh; L. Gordon; A.F. LoBuglio; J. Rosenberg; B. Alkuzweny; et al.

Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy
Annals of Oncology. 2001;12(1):109-114.

59
121.
2001

L.I. Gordon

Gemtuzumab ozogamicin (Mylotarg) and hepatic veno-occlusive disease: Take two acetaminophen, and ...
Bone Marrow Transplantation. 2001;28(9):811-812.

11
122.
2001

G.A. Wiseman; L.I. Gordon; T.E. Witzig; S. Spies; J.L. Murray; N.L. Bartlett; I.W. Flinn; M.S. Czuczman; C. Emmanouilides; J. Rosenberg; et al.

Zevalin radioimmunotherapy is not associated with significant or prolonged depletion of t cells or natural killer cells
Blood. 2001;96(11 PART II):252b.

4
123.
2000

Howard S. Hochster; Martin M. Oken; Jane N. Winter; Leo I. Gordon; Bruce G. Raphael; John M. Bennett; Peter A. Cassileth

Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and and long-term follow- up - A report from the Eastern Cooperative Oncology Group
Journal of Clinical Oncology. 2000;18(5):987-994.

75
124.
1999

Myron Czuczman; A.J. Grillo-López; C.A. White; M. Saleh; L. Gordon; A.F. LoBuglio; C. Jonas; D. Klippenstein; B. Dallaire; C. Varns

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
Journal of Clinical Oncology. 1999;17(1):268-276.

711
125.
1999

Peter H. Wiernik; Leo I. Gordon; Martin M. Oken; Jules E. Harris; Michael J. O'Connell

Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: A phase II study (P-H482) of the Eastern Cooperative Oncology Group
Leukemia and Lymphoma. 1999;35(3-4):375-377.

0
126.
1999

Gregory A. Wiseman; Christine A. White; Thomas E. Witzig; Leo I. Gordon; Christos Emmanouilides; Andrew Raubitschek; Nalini Janakiraman; John Gutheil; Russell J. Schilder; Stewart Spies; et al.

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a ⁹⁰Y-labeled anti-CD20 monoclonal antibody
Clinical Cancer Research. 1999;5(10 SUPPL.):3281s-3286s.

82
127.
1999

Thomas E. Witzig; Christine A. White; Gregory A. Wiseman; Leo I. Gordon; Christos Emmanouilides; Andrew Raubitschek; Nalini Janakiraman; John Gutheil; Russell J. Schilder; Stewart Spies; et al.

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20⁺ B-cell non-Hodgkin's lymphoma
Journal of Clinical Oncology. 1999;17(12):3793-3803.

444
128.
1999

Leo I. Gordon; Hau C. Kwaan

Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient
Seminars in Thrombosis and Hemostasis. 1999;25(2):217-221.

66
129.
1999

R.T. Hoppe; R. Abrams; S. Bernstein; P. Bierman; C.D. Bloomfield; J. Cox; L. Gordon; S. Horning; M. Kaminski; G. Love; et al.

NCCN practice guidelines for Hodgkin's disease
ONCOLOGY. 1999;13(5 A):78-110.

3
130.
1999

Vonda K. Douglas; Leo I. Gordon; Charles L. Goolsby; Christine A. White; LoAnn C. Peterson

Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma
American Journal of Clinical Pathology. 1999;112(6):844-853.

17
131.
1999

M.B. Kleinman; E.L. Wiley; M. Guo; A.W. Rademaker; M. Villa; M.S. Tallman; S.B. Newman; L.I. Gordon; J.N. Winter

Immunohistochemical detection of breast cancer cells in paired peripheral blood progenitor cell specimens collected after cytokine or cytokine and myelosuppressive chemotherapy
Bone Marrow Transplantation. 1999;23(12):1297-1301.

6
132.
1999

Leo I. Gordon; Mary Young; Edie Weller; Thomas M. Habermann; Jane N. Winter; John Glick; Chirantan Ghosh; Patrick Flynn; Peter A. Cassileth

A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity
Blood. 1999;94(10):3307-3314.

25
133.
1998

R.K. Burt; A.E. Traynor; B. Cohen; K.H. Karlin; F.A. Davis; D. Stefoski; C. Terry; L. Lobeck; E.J. Russell; C. Goolsby; et al.

T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: Report on the first three patients
Bone Marrow Transplantation. 1998;21(6):537-541.

70
134.
1998

M.S. Tallman; A.W. Rademaker; L. Jahnke; S.G. Brown; A. Bauman; C. Mangan; C. Kelly; H. Rubin; M.S. Kies; J. Shaw; et al.

Corrigendum: High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer (Bone Marrow Transplantation (1997) 20 (721-729))
Bone Marrow Transplantation. 1998;21(8):861.

0
135.
1998

Jr. Link C.J.; R.K. Burt; A.E. Traynor; W.R. Drobyski; T. Seregina; J.P. Levy; L. Gordon; S.T. Rosen; W.H. Burns; B. Camitta; et al.

Adoptive immunotherapy for leukemia: Donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction
Human Gene Therapy. 1998;9(1):115-134.

36
136.
1998

Lynn R. Kong; Cheng-Fang Huang; David Hakimian; Daina Variakojis; Leonard Klein; Timothy M. Kuzel; Leo I. Gordon; Connie Zanzig; Eric Wollins; et al.

Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma
Cancer. 1998;82(5):957-964.

24
137.
1998

Jane N. Winter; Janet Andersen; John C. Reed; Stanislaw Krajewski; Daina Variakojis; Kenneth D. Bauer; Richard I. Fisher; Leo I. Gordon; Martin M. Oken; Shuwei Jiang; et al.

BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: An Eastern Cooperative Oncology Group and Southwest Oncology Group Cooperative Laboratory Study
Blood. 1998;91(4):1391-1398.

33
138.
1997

M.S. Tallman; A.W. Rademaker; L. Jahnke; S.G. Brown; A. Bauman; C. Mangan; C. Kelly; H. Rubin; M.S. Kies; J. Shaw; et al.

High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer
Bone Marrow Transplantation. 1997;20(9):721-729.

5
139.
1997

L.I. Gordon; H.C. Kwaan

Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
Seminars in Hematology. 1997;34(2):140-147.

67
140.
1996

Jane N. Winter; Janet Andersen; Daina Variakojis; Leo I. Gordon; Richard I. Fisher; Martin M. Oken; Richard S. Neiman; Shuwei Jiang; Kenneth D. Bauer

Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas
Blood. 1996;88(10):3919-3925.

17
141.
1996

Michael A. LaCombe; Bharat B. Mittal; Laura A. Colangelo; Alfred W. Rademaker; William N. Brand; Harold Kim; Leo I. Gordon; John M. Merrill

Management of early-stage Hodgkin's lymphoma: The radiation oncology experience at Northwestern University/Northwestern Memorial Hospital
American Journal of Clinical Oncology: Cancer Clinical Trials. 1996;19(3):235-240.

1
142.
1996

L.I. Gordon; J. Anderson; T.M. Habermann; J.N. Winter; J. Glick; R.J. Schilder; P. Cassileth

Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: Determination of the maximum-tolerated dose of ProMACE-CytaBOM
Journal of Clinical Oncology. 1996;14(4):1275-1281.

20
143.
1996

M.S. Tallman; H.J. Miller; C. Anzig; A. Radmaker; L. Gordon; D. Hakimian; D. Variakojis; P. Stiff; S. French; A.B. Benson

All-trans retinoic acid, low-dose cytosine arabinoside and granulocyte colony-stimulating factor in acute myelogenous leukemia: update of an illinois cancer center phase d pilot study
Experimental Hematology. 1996;24(9):1125.

2
144.
1996

J.N. Winter; H.M. Lazarus; A. Rademaker; M. Villa; C. Mangan; M. Tallman; L. Jahnke; L. Gordon; S. Newman; K. Byrd; et al.

Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells
Journal of Clinical Oncology. 1996;14(1):277-286.

55
145.
1996

W.F. Ward; J.E. Moulder; B.L. Fish; A. Molteni; L.I. Gordon; J.M. Taylor

Acute lung reactions in a rat model of post-bone marrow transplantation pneumonitis
FASEB Journal. 1996;10(3):A108.

0
146.
1995

L.I. Gordon; J. Andersen; J. Colgan; J. Glick; G.D. Resnick; M. O'Connell; P.A. Cassileth

Advanced diffuse non-Hodgkin's lymphoma: Analysis of prognostic factors by the International Index and by lactic dehydrogenase in an Intergroup study
Cancer. 1995;75(3):865-873.

15
147.
1995

L.I. Gordon; S.G. Brown; M.S. Tallman; A.W. Rademaker; S.A. Weitzman; H.M. Lazarus; C.H. Kelley; C. Mangan; H. Rubin; R.M. Fox; et al.

Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: Possible implications for treatment related toxicity
Free Radical Biology and Medicine. 1995;18(3):383-389.

43
148.
1994

O. Kucuk; J. Stoner-Picking; S. Yachnin; L.I. Gordon; R.M. Williams; L.J. Lis; M.P. Westerman

Inhibition of cytolytic T lymphocyte activity by oxysterols
Lipids. 1994;29(9):657-660.

12
149.
1994

Mark Hoffman; Martin S. Tallman; David Hakimian; Dale Janson; Denise Hogan; Daina Variakogis; Timothy Kuzel; Leo I. Gordon; Kanti Rai

2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma
Journal of Clinical Oncology. 1994;12(4):788-792.

68
150.
1994

J.N. Winter; C. Mangan; K. Bryd; M. Tallman; L. Gordon; L. Jahnke; H. Lazarus; B. Cooper; E. Crum; N. Horvath

Combined therapy with rG-CSF and GM-CSF for the mobilization of hematopoietic progenitor cells.
Progress in clinical and biological research. 1994;389:463-470.

0
151.
1993

L.I. Gordon; G.I. Shapiro; S.T. Rosen; M.S. Kies; S. Prachand; H.M. Vriesendorp

Separation of chronic lymphocytic leukemia (CLL) cells by a discontinuous density gradient: Correlation with clinical stage
International Journal of Oncology. 1993;2(6):981-984.

0
152.
1993

C.F. Von Gunten; L.I. Gordon

Treatment of advanced, aggressive non-Hodgkin's lymphoma
Current Opinion in Oncology. 1993;5(5):791-796.

4
153.
1993

M.D. Herman; L.I. Gordon; K. Kaul; D. Variakojis; K. Bauer; R.M. Levy

Systemic T-cell lymphoma presenting with isolated neurological dysfunction and intraparenchymal brain lesions. Case report
Journal of Neurosurgery. 1993;78(6):997-1001.

5
154.
1993

L.I. Gordon; J. Andersen; S. Gregory; J. Mazza; P. Chervenick; R.G. Hahn; M.J. O'Connell

A VM 26-based regimen for patients with previously untreated non-Hodgkin lymphoma: Prolonged disease-free survival in patients younger than 60 years of age: A Phase II trial of the Eastern Cooperative Oncology Group
Cancer. 1993;71(2):464-470.

1
155.
1993

W. Hryniuk; L.I. Gordon; D. Harrington; J. Andersen

CHOP versus m-BACOD in non-Hodgkin's lymphoma [2]
New England Journal of Medicine. 1993;328(8):581.

1
156.
1993

L.I. Gordon; S.A. Weitzman

Inflammation and cancer
Cancer Journal. 1993;6(5):257-261.

23
157.
1993

T.M. Kuzel; S.T. Rosen; L.I. Gordon; J. Winter; E. Samuelson; K. Kaul; H.H. Roenigk; P. Nylen; T. Woodworth

Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB₄₈₆IL-2: Efficacy in mycosis fungoides and other non-Hodgkin's lymphomas
Leukemia and Lymphoma. 1993;11(5-6):369-377.

23
158.
1993

A.E. Traynor; S.A. Weitzman; L.I. Gordon

Bacterial phosphatidylcholine-preferring phospholipase C reversibly inhibits the membrane component of the NADPH oxidase in human polymorphonuclear leukocytes: Implications for host defense
Cellular Immunology. 1993;152(2):582-593.

3
159.
1992

O. Kucuk; J. Stoner-Picking; S. Yachnin; L.I. Gordon; R.M. Williams; L.J. Lis; M.P. Westerman

Inhibition of NK cell-mediated cytotoxicity by oxysterols
Cellular Immunology. 1992;139(2):541-549.

22
160.
1992

Leo I. Gordon; David Harrington; Janet Andersen; Joseph Colgan; John Glick; Richard Neiman; Risa Mann; Gene D. Resnick; Maurice Barcos; Arlan Gottlieb; et al.

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
New England Journal of Medicine. 1992;327(19):1342-1349.

244
161.
1991

S.H. McDunn; J.N. Winter; D. Variakojis; A.W. Rademaker; J.H. Von Roenn; M.S. Tallman; L.I. Gordon; K.D. Bauer

Human immunodeficiency virus-related lymphomas: A possible association between tumor proliferation, lack of ploidy anomalies, and immune deficiency
Journal of Clinical Oncology. 1991;9(8):1334-1340.

1
162.
1991

A.S.D. Spiers; J.H. Weens; J.M. Rowe; T.J. Smith; J. Horton; L.I. Gordon; J.H. Glick

Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (The BBVDD regimen)
American Journal of Clinical Oncology: Cancer Clinical Trials. 1991;14(6):519-525.

0
163.
1991

L.I. Gordon; D. Weiss; S. Prachand; S.A. Weitzman

Scavenging of superoxide anion by phosphorylethanolamine: studies in human neutrophils and in a cell free system
Free Radical Research Communications. 1991;15(1):65-71.

5
164.
1990

S.A. Weitzman; L.I. Gordon

Inflammation and cancer: Role of phagocyte-generated oxidants in carcinogenesis
Blood. 1990;76(4):655-663.

347
165.
1990

M.J. Vasconcelles; S.A. Weitzman; S.N. Lee; S. Prachard; L.I. Gordon

Inhibition of human polymorphonuclear leukocyte respiratory burst activity and aggregation by 6-ketocholestanol
Free Radical Research Communications. 1990;8(3):185-193.

1
166.
1990

L.I. Gordon; C. Schmeichel; S. Prachand; S.A. Weitzman

Inhibition of polymorphonuclear leukocyte oxidative metabolism by exogenous phospholipase C
Cellular Immunology. 1990;128(2):503-515.

0
167.
1989

P.S. Pegram; J.P. Phair; R. McMahan; R.L. Murphy; L.I. Gordon; H. Washton; C. Faubion; S. Saviteer; M.S. Cohen

Prospective comparative trial of short course (four day) and continuous tobramycin in combination with cefoperazone or mezlocillin in febrile, granulocytopenic patients
Journal of Antimicrobial Chemotherapy. 1989;24(4):591-604.

1
168.
1988

C.A. Radosevich; L.I. Gordon; S.C. Weil; R.J. Marder; S.T. Rosen

Complete resolution of pure red cell aplasia in a patient with chronic lymphocytic leukemia following antithymocyte globulin therapy
Journal of the American Medical Association. 1988;259(5):723-725.

3
169.
1988

M.S. Kies; L.I. Gordon; S.T. Rosen; O. Kucuk; H.M. Vriesendorp

Autologous bone marrow transplantation in breast cancer: separation of clonogenic tumor cell colonies by gradient fractionation
Experimental Hematology. 1988;16(3):190-194.

9
170.
1988

R. Ganz; E. Olinger; D. Variakojis; L. Gordon

Mycosis fungoides with gastrointestinal involvement
Gastrointestinal Endoscopy. 1988;34(6):478-481.

1
171.
1987

D. Kaufman; L.I. Gordon; D. Variakojis; W.A. Caro; R. Marder; M. Jumbelic; H.H. Roenigk Jr.

Successfully treated Hodgkin's disease followed by mycosis fungoides: Case report and review of the literature
Cutis. 1987;39(4):291-296.

5
172.
1987

S.T. Rosen; A.M. Zimmer; R. Goldman-Leikin; L.I. Gordon; J.M. Kazikiewicz; E.H. Kaplan; D. Variakojis; R.J. Marder; M.S. Dykewicz; A. Piergies

Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an ¹³¹I-labeled monoclonal antibody: An Illinois cancer council study
Journal of Clinical Oncology. 1987;5(4):562-573.

41
173.
1987

Leo I. Gordon; Hau C. Kwaan; Ennio C. Rossi

Deleterious effects of platelet transfusions and recovery thrombocytosis in patients with thrombotic microangiopathy
Seminars in Hematology. 1987;24(3):194-201.

51
174.
1986

J.N. Winter; L.I. Gordon; W.W. Hauck; D. Variakojis

Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphoma of the unfavorable histologic subtypes
Cancer Treatment Reports. 1986;70(10):1243-1244.

0
175.
1986

S.T. Rosen; R. Gore; J. Brennan; L.I. Gordon; D. Variakojis; M.M. Rosenbaum; W. Caro; H. Roenigk Jr.

Evaluation of computed tomography and radionuclide scanning in the staging of cutaneous T-cell lymphoma
Archives of Dermatology. 1986;122(8):884-886.

3
176.
1985

M.S. Kies; L.I. Gordon; W.W. Hauck; Y. Krespi; R.H. Ossoff; B.C. Pecaro; C. Yuska; C.H. Lamut; W.N. Brand; S.K. Chang

Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer
Otolaryngology - Head and Neck Surgery. 1985;93(2):199-205.

17
177.
1985

V.L. Rose; L.I. Gordon

Idiopathic thrombocytopenic purpura in pregnancy. Successful management with immunoglobulin infusion
Journal of the American Medical Association. 1985;254(18):2626-2628.

2
178.
1984

O. Kucuk; L.I. Gordon; M.S. Kies; S. Spies; W. Spies; H.M. Vriesendorp

Estimation of hemopoietic potential by CFU-c and bone marrow scan in cancer patients
Experimental Hematology. 1984;12(2):101-106.

1
179.
1984

Merrill S. Kies; Bernard C. Pecaro; Leo I. Gordon; Walter W. Hauck; Michael J. Kraut; Yosef Krespl; Robert H. Ossoff; Cynthia Schiff; Ramananda Shetty; George A. Sisson

Preoperative combination chemotherapy for advanced stage head and neck cancer. Promising early results
The American Journal of Surgery. 1984;148(3):367-371.

1
180.
1984

Y. Ueshima; J.D. Rowley; D. Variakojis; J. Winter; L. Gordon

Cytogenetic studies on patients with chronic T cell leukemia/lymphoma
Blood. 1984;63(5):1028-1038.

3
181.
1984

L.I. Gordon; S.T. Rosen; H.M. Vriesendorp; M.S. Kies; O. Kucuk

Separation of clonogenic tumor cells from small cell lung cancer bone marrow and small cell lung cancer cell lines
Cancer Research. 1984;44(11):5404-5408.

0
182.
1983

R.A. Larson; L.I. Gordon; S. Yachnin

Neutrophil-assisted DNA synthesis by human lymphocytes in response to mevalonic acid; enhancement by cytochalasin B
Cellular Immunology. 1983;81(2):357-372.

1
183.
1983

S.T. Rosen; Z. Maciorowski; F. Wittlin; A.L. Epstein; L.I. Gordon; M.S. Kies; O. Kucuk; H.C. Kwaan; H. Vriesendorp; J.N. Winter

Estrogen receptor analysis in chronic lymphocytic leukemia
Blood. 1983;62(5):996-999.

9
184.
1982

S. Nand; L.I. Gordon; E. Brestan; C. Harris; T. Brandt

Benign hepatic cyst in a patient on antiestrogen therapy for metastatic breast cancer
Cancer. 1982;50(9):1882-1883.

1
185.
1980

L.I. Gordon; W.J. Miller; R.F. Branda; E.D. Zanjani; H.S. Jacob

Regulation of erythroid colony formation by bone marrow macrophages
Blood. 1980;55(6):1047-1050.

2
186.
1980

P.C. Hoffman; H.M. Golomb; J.D. Bitran; T.R. DeMeester; L. Cohen; M.L. Griem; J.A. Cooksey; U. Mintz; L.I. Gordon; R.K. Desser; et al.

Small-cell carcinoma of the lung: A five-year experience with combined modality therapy
Cancer. 1980;46(12):2550-2556.

1
187.
1980

L.I. Gordon; J. Bass; S. Yachnin

Inhibition of human polymorphonuclear leukocyte chemotaxis by oxygenated sterol compounds
Proceedings of the National Academy of Sciences of the United States of America. 1980;77(7 II):4313-4316.

0
188.
1980

Harvey M. Golomb; Donald L. Sweet; John E. Ultmann; J.Bruce Miller; Jean J. Kinzie; Leo I. Gordon

Importance of substaging of stage III Hodgkin's disease
Seminars in Oncology. 1980;7(2):136-143.

1
189.
1979

L.I. Gordon; J. Bass; S. Yachnin

Inhibition of polymorphonuclear leukocyte (PMN) chemotaxis by oxygenated sterol compounds (OSC)
Clinical Research. 1979;27(4):688A.

0
190.
1979

S. Yachnin; R.A. Streuli; L.I. Gordon; R.C. Hsu

Alteration of peripheral blood cell membrane function and morphology by oxygenated sterols; a membrane insertion hypothesis.
Current topics in hematology. 1979;2:245-271.

4
191.
1979

L.I. Gordon; W. Hrushesky; M.M. Oken; N.E. Kay; R.E. Rydell

Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder: Response to chemotherapy in two cases
Medical and Pediatric Oncology. 1979;7(2):111-116.

0
192.
1979

L.I. Gordon; S.D. Douglas; N.E. Kay; O. Yamada; E.F. Osserman; H.S. Jacob

Modulation of neutrophil function by lysozyme. Potential negative feedback system of inflammation
Journal of Clinical Investigation. 1979;64(1):226-232.

25
193.
1978

N.E. Kay; L.I. Gordon; S.D. Douglas

Autoimmune hemolytic anemia in association with monoclonal IgM(k) with anti-i activity
American Journal of Medicine. 1978;64(5):845-850.

0

Leo I Gordon Feinberg School of Medicine, Feinberg Clinical, Medicine, Hematology Oncology Division

Leo I Gordon

193 Publications

Leo I Gordon
Feinberg School of Medicine, Feinberg Clinical, Medicine, Hematology Oncology Division